[Effects of XXXX on serum lipid and lipoprotein levels in @entity1 with @entity46 ].

@entity1 @entity2627 @entity1674 @entity9680 @entity1872 @entity18894 @entity46 @entity1718 @entity165
Danazol was given to 16 @entity1 with @entity46 in daily doses of 200 to 400mg for 4 to 6 months, and the change in serum lipids and lipoproteins was analysed. @entity1872 decreased total @entity165 by an average of 22%, @entity1674 by 56%, phospholipids by 29%, free @entity1718 by 17% and lipid @entity2627 by 42%, among which reductions in total @entity165 (p less than 0.05) and lipid @entity2627 (p less than 0.01) were statistically significant when compared with the pretreatment levels. Levels of lipids in @entity9680 and VLDL also fell: @entity9680 - @entity165 by 43%, @entity9680 - @entity1674 by 68%, @entity9680 -phospholipids by 40%, VLDL- @entity165 by 73%, VLDL- @entity1674 by 71% and VLDL-phospholipids by 48%. The decrease in @entity9680 - @entity165 (p less than 0.05), @entity9680 - @entity1674 (p less than 0.05) and @entity9680 -phospholipids (p less than 0.001) was significant. Concurrently apolipoproteins and @entity18894 activity decreased: A-I by 28% (p less than 0.001), A-II by 7% (p less than 0.05) and @entity18894 by 35%. In contrast, LDL- @entity165 increased, though slightly. Therefore, the atherogenic index defined as the ratio of LDL-c/ @entity9680 -c rose as much as 98% of the initial value. These changes seem to have arisen from impairment in the VLDL- @entity9680 cycle. The decrease in VLDL and increase in LDL indicated that VLDL was catabolised and converted to LDL at a normal rate while the formation of @entity9680 was impaired probably due to the low activity of @entity18894 and low level of apo A-I and A-II.(ABSTRACT TRUNCATED AT 250 WORDS)
